A STUDY OF COMPARATIVE EFFICIENCY OF ORAL MINI PULSE THERAPY VERSUS ORAL ACITRETIN IN GENERALISED LICHEN PLANUS

P. Guru Prasad1, T. S. Mohan Rao2, Shalini3, Ramanamurthy4, Anila Sunadini P5, Padmasri Somala Y6, Priyadarshini7, Rajesh Kumar Godugula8

HOW TO CITE THIS ARTICLE:
P. Guru Prasad, T. S. Mohan Rao, Shalini, Ramanamurthy, Anila Sunadini, Padmasri Somala, Priyadarshini, Rajesh Kumar Godugula. "A Study of Comparative Efficiency of Oral Mini Pulse Therapy versus Oral Acitretin in Generalised Lichen Planus". Journal of Evolution of Medical and Dental Sciences 2015; Vol. 4, Issue 80, October 05; Page: 13956-13962, DOI: 10.14260/jemds/2015/1988

ABSTRACT: BACKGROUND: Lichen planus is a chronic inflammatory disease that affects skin, mucous membranes, hair and nails. There are several drugs both topical and systemic for the treatment of lichen planus. AIMS AND OBJECTIVES: Present study was done to compare the efficacy between oral mini pulse therapy with betamethasone and with acetretin in the management of generalised lichen planus. MATERIALS AND METHODS: The study was carried out on patients who were clinically diagnosed as generalised lichen planus, attending the outpatient department of dermatology, venereology and leprosy, King George hospital, affiliated to Andhra medical college, Vishakhapatnam from November 2011 to December 2012. A total of 60 patients were included in study and divided into two equal groups. Group1 patients were treated with 0.1mg/kg of oral betamethasone given on 2 consecutive days in a week till 8 weeks and tapered. Group 2 patients were treated with 0.5mg/kg of acetretin for 8 weeks and tapered. INCLUSION CRITERIA: All patients of age group in between 11-60 years, of either sex, suffering from lichen planus of duration >3 months, and women in group 2 who were in reproductive age group on two methods of contraception were included. EXCLUSION CRITERIA: Pregnant and lactating women, in Group 1: patients suffering from diabetes, hypertension, peptic ulcer disease, renal, hepatic, heart disease or tuberculosis, in Group 2: patients with abnormal lipid profile, diabetes, hypertension, renal, liver or heart disease were excluded. RESULTS: out of 60 patients enrolled in study, 2 patients from group 1 and 5 patients from group 2 were dropped from study and results were concluded. Majority of patients were in age group of 31-60 (78.3%) with male to female ratio of 2.1:1.Group 1 patients at the end of 8 weeks response was seen in 92.8%, with relapse rate of 15.38% after 6 months of follow up. Group 2 patients at end of 8 weeks response was seen in 72 % with relapse rate of 5.5%. CONCLUSION: In our study oral mini pulse therapy with betamethasone has early onset of action and with a complete response in majority of patients with slightly more relapse rate when compared to oral acetretin. Oral acetretin has less relapse rate due to prolonged half-life. KEYWORDS: Lichen planus, Mini pulse therapy, Betamethasone, Acetretin.

INTRODUCTION: Lichen planus (LP) is an immunologically mediated inflammatory disorder of skin, hair, nails and mucous membranes characterised by well-defined purple pruritic papular lesions mainly distributed in flexor aspects of extremities.[1] The main pathogenic mechanism underlying lichen planus lesions is keratinocyte apoptosis induced by cytotoxic T cells and NK cells initiated by specific self-antigens in genetically predisposed individuals with several predisposing, triggering or exacerbating factors treatment of lichen planus is aimed at suppression or modification of inflammatory response. Generalised lichen planus is treated more commonly used systemic agents like corticosteroids, acitretin, sulfasalazine, dapsone, cyclosporine, azathioprine and topical PUVA
and NBUVB. The present study was done to compare the efficacy between oral betamethasone mini pulse therapy and oral acitretin and to know the relapse rate.[2,3,4,5,6,7,8,9,10]

MATERIALS AND METHODS: The study was carried out on patients who were clinically diagnosed as generalised lichen planus, attending the outpatient department of dermatology, venereology and leprosy, King George hospital, affiliated to Andhra medical college, Visakhapatnam from November 2011 to December 2012. A total of 60 patients were included in study and divided into two equal groups. Informed consent was taken. Details of patient like age, sex, occupation, patients with generalised lichen planus of >3months duration, symptoms, past history was taken. Routine blood investigations like hemogram, total leucocyte count, platelet count, random blood glucose levels, renal function tests, liver function tests, lipid profile, 2D-ECHO, chest X ray P-A view and skin biopsy were done to rule out systemic disease and to confirm LP. After confirming diagnosis and ruling out the systemic diseases, the patients were randomly divided into 2 groups. Group1 patients were treated with 0.1mg/kg of oral betamethasone given on 2 consecutive days in a week till 8 weeks and tapered. Group 2 patients were treated with 0.5mg/kg of acitretin for 8 weeks and tapered. Both the groups were followed up for 6months.

Inclusion Criteria: All patients of age group in between 11-60 years, of either sex, suffering from generalised lichen planus of duration >3 months were included.in group 2 women in reproductive age group followed two methods of contraception were included.

Exclusion Criteria: Pregnant and lactating women, in Group 1: patients suffering from diabetes, hypertension, peptic ulcer disease, renal, hepatic, heart disease or tuberculosis, in Group 2: patients with abnormal lipid profile, diabetes, hypertension, renal, liver or heart disease were excluded.

Data analysis: the data is analysed using percentages, ratios and p-values.

RESULTS: Total of 60 confirmed cases of generalised lichen planus were selected after considering exclusion criteria. Other variants of lichen planus were excluded from study. Results were analysed and tabulated. 

Age Distribution: (Table 1) Maximum number of cases 73% were detected in age group of 31-40, least number of cases 2% were in age group of 11-20 years age group. Sex distribution (Table 2): 40 out of 60 were female patients with female to male ratio of 2.1:1. Out of 60 patients severe pruritus was observed in 66.66% of cases, moderate pruritus in 21.66% and mild pruritus in 5%, no pruritus in 2% of cases. Of the clinical variants of lichen planus patients with generalised cutaneous involvement were included in study. out of 60 patients, 50% are having classical lichen planus lesions, where as 26.6% has classic LP lesions with mucosal involvement, 6% has hypertrophic lesions, 3% with classical lesions and follicular lesions and 8 % has hypertrophic lesions alone.

Among 30 patients in group 1 there are 2 drop outs, and response to treatment after 8 weeks is 92.8%. Among 30 patients in group 2 there are 5 drop outs, and the response rate is 72% slightly low when compared to group 1. The difference observed among two groups was statistically significant with a p- value <0.05. In 51-60 year age group the response rate was 66.6% in both groups. Response rate was 80-100% and 66-70% between ages of 21-50 years with oral mini pulse and oral acitretin respectively. (Table 4) Response rate was 100% with oral mini pulse therapy in...
11-20 years age group. Response rate was slightly more in females treated with oral mini pulse and males treated with acitretin. [Table 5] Side effects most commonly noted in group 1 were gastritis (53%) and weight gain (35.7%) [Table 6] Side effects most commonly noted in group 2 were dry lips (80%), nausea, and vomiting and hair loss (20% each). Serum triglycerides were elevated only in 1/25 patients. [Table 7]

Among 28 patients in group 1 there is a relapse rate of 3.84%, 7.69% and 15.38% was observed at the end of 2nd, 4th and 6th months of follow up respectively. [Table 8]

**DISCUSSION:** Lichen planus is an immune mediate disease affecting skin, hair, nails and mucous membranes with genetic predisposition and various triggering factors. There are many clinical variants of disease. The disease can be generalised where systemic therapies were given in order to treat the disease. Out of all systemic modalities oral corticosteroids, are the mainstay of therapy, in present study an attempt was made to compare the efficacy between oral mini pulse therapy with betamethasone, and oral acitretin.

**Age Distribution:** In present study, Out of 60 patients, 78.33% of lichen planus cases were in age group of 30-60 years which is comparable to western study by melgren et al. Sex distribution (Table 9): In present study female patients outnumbered males in a ratio of 2.1:1, which is nearly comparable to study by vijay kumar et al, In a study done by ramesh et al, male patients outnumbered females, (54.28%) patients were males and 16(45.71%) were females. Present study out of 60 patients, 40(66.66%) patients had severe pruritus with sleep disturbance affecting quality of life and itching subsided around 4-6 weeks after starting treatment and is slightly early in patients treated with mini pulse therapy. Severe pruritus was seen in 16(45.7%) patients in study done by ramesh et al., present study severe itching was present in higher percentage.

**Response Rate:** Group 1 patients at the end of 8 weeks, response was seen in 92.8%, with relapse rate of 15.38% after 6 months of follow up. The relapse rate was compared to study done by ramesh et al, (14%) Corticosteroids have been used as a therapeutic modality for LP topically, intralesionally or systemically. Oral mini pulse therapy was taken in order to decrease the side effects of pulse therapy and improve the efficacy. Side effects are less with oral mini pulse therapy than with daily therapy. The most common side effects in this study group were gastritis, weight gain and nausea seen in around all patients (25/28).

In study by ramesh et al, side effects due to treatment were seen in 20(57.1%) patients; most commonly weight gain, insomnia and epigastric pain. Group 2 patients at end of 8 weeks complete response was seen in 72% with relapse rate of 5.5%. As acitretin has long t 1/2 when compared with oral mini pulse and due re-esterification a small amount of drug is released from fat stores so therapeutic effect is maintained even after stopping the drug. So there are few relapses in patients treated with acitretin group. The response to therapy was comparable with study done by Laurberg et al, patients treated with acitretin (30mg/day) showed reponse rate of 64%, at the end of 8th week which is slightly less when compared to present study. Regarding side effects typical retinoid side effects were seen in only 80% of patients treated with acitretin but in study done by Laurberg et al typical retionoid side effects were seen in all patients (Table 10).
CONCLUSION: The present study concluded that oral mini pulse treatment has good response rate and more symptomatic relief but with high relapse rate, acitretin in treated group has less relapse rate. More comparative studies has to be done in future.

REFERENCES:

1. Rivers JK, Jackson R, Orizaga M. Who was Wickham and what are his striae? Int J Dermatol 1986; 25: 611–3.
2. Chan ES, Thornhill M, Zakrzewska J. Interventions for treating oral lichen planus. Cochrane Database Syst Rev 2000; 2: CD001168.
3. Kellet JK, Ead RD. Treatment of lichen planus with short course of oral prednisolone. Br J Dermatol 1990; 123: 550–1.
4. Brice SL, Barr RJ, Rattet JP. Childhood lichen planus, a question of therapy. J Am Acad Dermatol 1980; 3: 370–6.
5. Laurberg G, Geiger JM, Hjorth N et al. Treatment of lichen planus with acitretin. J Am Acad Dermatol 1991; 24: 434–7.
6. Libow LF, Coots NV. Treatment of lichen planus and lichen nitidus with itraconazole: reports of six cases. Cutis 1998; 62: 247–8.
7. Bauzá A, España A, Gil P et al. Successful treatment of lichen planus with sulfasalazine in 20 patients. Int J Dermatol 2005; 44: 156-7.
8. Pavlotsky F, Nathansohn N, Kriger G et al. Ultraviolet-B treatment for cutaneous lichen planus: our experience with 50 patients. Photodermatol Photoimmunol Photomed 2008; 24: 83–6.
9. Taneja A, Taylor CR. Narrow-band UVB for lichen planus treatment. Int J Dermatol 2002; 41: 282–3.
10. Wackernagel A, Legat FJ, Hofer A et al. Psoralen plus UVA vs. UVB-311 nm for the treatment of lichen planus. Photodermatol Photoimmunol Photomed 2007; 23: 15–9.
11. Ramesh M, Balachandran C, Shennoi S D, Rai VM. Efficacy of steroid oral mini-pulse therapy in lichen planus: An open trial in 35 patients. Indian J Dermatol Venereol Leprol 2006; 72: 156-7.
12. Verma KK, Mittal R, Manchanda Y, Khaitan BK. Lichen planus treated with betamethasone oral minipulse therapy. Indian J Dermatol Venereol Leprol 2000; 66:34.
13. Kelett JK, Ead RD. Treatment of lichen planus with a short course of oral prednisolone. Br J Dermatol 1990; 12 3:550-51.
14. Laurberg G, Geiger JM, Hjorth N et al. Treatment of lichen planus with acitretin: A double-blind, placebo-controlled study in 65 patients. J Am Acad Dermatol. 1991 Mar; 24(3): 434-7.

| Age       | Number of Cases | Percentage % |
|-----------|-----------------|--------------|
| 11-20 years | 6               | 10%          |
| 21-30 years | 7               | 11.6%        |
| 31-40 years | 22              | 36.66%       |
| 41-50 years | 17              | 28.33%       |
| 51-60 years | 8               | 13.3%        |
| Total     | 60              | 100%         |

Table 1: Age Distribution in Present Study
**Table 2: Sex Distribution in Present Study**

| Sex     | Number of Cases | Percentage % |
|---------|-----------------|--------------|
| Males   | 20              | 31.66%       |
| Females | 40              | 66.66%       |
| **Total** | **60**           | **100%**     |

**Table 3: Response of the Disease in Relation to Duration of Therapy and Modality of Treatment**

| Modality of Treatment | Total Number of Patients Tried | Total Number of Patients Completed Treatment Excluding Dropouts | Resolution at the End of 4 Weeks | Resolution at the End of 6 Weeks | Resolution at the End of 8 Weeks | Total Number of Patients with Response at the End of 8 Weeks. |
|-----------------------|-------------------------------|---------------------------------------------------------------|----------------------------------|----------------------------------|-------------------------------|---------------------------------------------------------------|
| Oral Betamethasone    | 30                            | 28                                                            | 5                                | 11                               | 10                            | 26(92.8%)                                                      |
| Mini Pulse Therapy    |                               |                                                               |                                  |                                  |                               |                                                               |
| Oral Acitretin        | 30                            | 25                                                            | 2                                | 6                                | 10                            | 18(72%)                                                       |

**Table 4: Response rate in relation to age after deducing dropouts**

| Age in Years | ORAL MINI PULSE | ORAL ACITRETIN |
|--------------|-----------------|----------------|
|              | No. of Patients Treated | No. of Patients Responded | Percentage | No. of Patients Treated | No. of Patients Responded | Percentage |
| 11-20years   | 5               | 5               | 100%       | 0                    | 0                       | 0%          |
| 21-30years   | 4               | 4               | 100%       | 3                    | 2                       | 66.6%       |
| 31-40years   | 11              | 11              | 100%       | 9                    | 7                       | 77.7%       |
| 41-50years   | 5               | 4               | 80%        | 10                   | 7                       | 70%         |
| 51-60years   | 3               | 2               | 66.6%      | 3                    | 2                       | 66.66%      |

**Table 5: Response Rate in Relation to Sex**

| Sex     | ORAL MINI PULSE | ORAL ACITRETIN |
|---------|-----------------|----------------|
|         | No. of Patients | No of Patients Responded | Percentage | No. of Patients | No of patients Responded | Percentage |
| Male    | 10              | 9               | 90%        | 8                  | 6                       | 75%        |
| Female  | 18              | 17              | 94.4%      | 17                 | 12                      | 70.58%     |
### Table 6: Adverse Effects in Group 1 - Oral Mini Pulse Therapy

| Adverse Effects           | No. of Patients | Percentage |
|---------------------------|----------------|------------|
| Gastritis                 | 15             | 53%        |
| Weight Gain               | 10             | 35.7%      |
| Nausea /Vomiting          | 2              | 7%         |
| Acneiform Eruptions       | 2              | 7%         |
| Insomnia                  | 1              | 3.5%       |

### Table 7: Adverse Effects in Group 2 - Oral Acitretin Therapy

| Adverse Effects                     | No. of patients | Percentage |
|-------------------------------------|-----------------|------------|
| Dry Lips                            | 20              | 80%        |
| Nausea /Vomiting                    | 5               | 20%        |
| Hair Loss                           | 5               | 20%        |
| Xerosis of Skin                     | 4               | 16%        |
| Pruritus                            | 4               | 16%        |
| Serum Triglyceride Elevation        | 1               | 4%         |

### Table 8: Relapse Rate After 6 Months of Follow up After Treatment in Both Groups

| Group                  | <2 months | 3-4 months | 5-6 months |
|------------------------|-----------|------------|------------|
| No of Patients with Relapse | Percentage | No of Patients with Relapse | Percentage | No of Patients with Relapse | Percentage |
| Oral Mini Pulse        | 1         | 3.84%      | 2          | 7.69%      | 4          | 15.38%     |
| Oral Acitretin         | 0         | 0%         | 0          | 0%         | 1          | 5.5%       |

### Table 9: Comparison of Sex Ratio Between Present Study and Ramesh et al.

| Gender           | Present Study | Ramesh et al. |
|------------------|---------------|---------------|
| Male             | 31.66%        | 54.28%        |
| Females          | 66.66%        | 45.71%        |
| Male: Female Ratio | 1:2.1        | 1.18:1        |

### Table 10: Comparison between Present Study with Acitretin and Study by Laurberg et al.

| Category                                      | Present Study with Acitretin | Laurberg et al. |
|-----------------------------------------------|------------------------------|-----------------|
| Total Patients in Study                       | 25                           | 65              |
| Response Rate                                 | 72%                          | 64%             |
| Side Effects Typical Retinoid Side Effects    | 80%                          | 100%            |
| Elevated Serum Triglycerides                  | 4%                           | None            |

---

Adverse Effects

Table 6: Adverse Effects in Group 1 - Oral Mini Pulse Therapy

| Adverse Effects     | No. of Patients | Percentage |
|---------------------|-----------------|------------|
| Gastritis           | 15              | 53%        |
| Weight Gain         | 10              | 35.7%      |
| Nausea /Vomiting    | 2               | 7%         |
| Acneiform Eruptions | 2               | 7%         |
| Insomnia            | 1               | 3.5%       |

Table 7: Adverse Effects in Group 2 - Oral Acitretin Therapy

| Adverse Effects                     | No. of patients | Percentage |
|-------------------------------------|-----------------|------------|
| Dry Lips                            | 20              | 80%        |
| Nausea /Vomiting                    | 5               | 20%        |
| Hair Loss                           | 5               | 20%        |
| Xerosis of Skin                     | 4               | 16%        |
| Pruritus                            | 4               | 16%        |
| Serum Triglyceride Elevation        | 1               | 4%         |

Table 8: Relapse Rate After 6 Months of Follow up After Treatment in Both Groups

| Group                  | <2 months | 3-4 months | 5-6 months |
|------------------------|-----------|------------|------------|
| No of Patients with Relapse | Percentage | No of Patients with Relapse | Percentage | No of Patients with Relapse | Percentage |
| Oral Mini Pulse        | 1         | 3.84%      | 2          | 7.69%      | 4          | 15.38%     |
| Oral Acitretin         | 0         | 0%         | 0          | 0%         | 1          | 5.5%       |

Table 9: Comparison of Sex Ratio Between Present Study and Ramesh et al.

| Gender           | Present Study | Ramesh et al. |
|------------------|---------------|---------------|
| Male             | 31.66%        | 54.28%        |
| Females          | 66.66%        | 45.71%        |
| Male: Female Ratio | 1:2.1        | 1.18:1        |

Table 10: Comparison between Present Study with Acitretin and Study by Laurberg et al.

| Category                                      | Present Study with Acitretin | Laurberg et al. |
|-----------------------------------------------|------------------------------|-----------------|
| Total Patients in Study                       | 25                           | 65              |
| Response Rate                                 | 72%                          | 64%             |
| Side Effects Typical Retinoid Side Effects    | 80%                          | 100%            |
| Elevated Serum Triglycerides                  | 4%                           | None            |
## AUTHORS:
1. P. Guru Prasad
2. T. S. Mohan Rao
3. Shalini
4. Ramanamurthy
5. Anila Sunadini
6. Padmasri Somala Y.
7. T. Priyadarshini
8. Rajesh Kumar Godugula

## PARTICULARS OF CONTRIBUTORS:
1. Associate Professor, Department of Dermatology, Andhra Medical College, Vishakapatnam.
2. Assistant Professor, Department of Dermatology, Andhra Medical College, Vishakapatnam.
3. Senior Resident, Department of Dermatology, Andhra Medical College, Vishakapatnam.
4. Professor, Department of Dermatology, Andhra Medical College, Vishakapatnam.
5. Professor and HOD, Department of Dermatology, Andhra Medical College, Vishakapatnam.
6. Junior Resident, Department of Dermatology, Andhra Medical College, Vishakapatnam.
7. Senior Resident, Department of Dermatology, Andhra Medical College, Vishakapatnam.
8. Junior Resident, Department of Dermatology, Andhra Medical College, Vishakapatnam.

## NAME ADDRESS EMAIL ID OF THE CORRESPONDING AUTHOR:
Dr. P. Guruprasad,
Associate Professor,
Department of Dermatology,
Andhra Medical College, Vishakapatnam.
E-mail: gpatnala@yahoo.co.in

Date of Submission: 29/09/2015.
Date of Peer Review: 29/09/2015.
Date of Acceptance: 30/09/2015.
Date of Publishing: 03/10/2015.

## FINANCIAL OR OTHER COMPETING INTERESTS: None